Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Berns Paul L.SEE REMARKS | Neumora TherapeuticsNMRA | Open-market sale | 02/17 | 02/19 | 9,819 sh | $3.51 | $34,464.69 | −0.1% |
Aurora Daljit SinghSEE REMARKS | Neumora TherapeuticsNMRA | Open-market sale | 02/17 | 02/19 | 6,165 sh | $3.56 | $21,947.4 | −6.9% |
Pinto JoshuaPresident | Neumora TherapeuticsNMRA | Open-market sale | 02/17 | 02/19 | 5,967 sh | $3.54 | $21,123.18 | −9.4% |
Milligan Michael LeeSEE REMARKS | Neumora TherapeuticsNMRA | Open-market sale10b5-1 plan | 02/17 | 02/19 | 1,436 sh | $3.57 | $5,126.52 | −6.4% |
Aurora Daljit SinghSEE REMARKS | Neumora TherapeuticsNMRA | Open-market sale10b5-1 plan | 25/11/11 | 25/11/13 | 114,703 sh | $2.68 | $307,404.04 | −100.0% |
Keith Crandell10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Robert Nelsen10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Clinton Bybee10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Steven Gillis10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Arch Venture Fund VII10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Arch Venture Partners VII10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Arch Venture Partners VII10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Kristina BurowDirector | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Arch Venture Partners VIII10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Arch Venture Fund VIII Overage10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Arch Venture Fund X10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Arch Venture Fund X Overage10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Arch Venture Partners X Overage10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Arch Venture Partners X10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |
Arch Venture Partners X10% Owner | Neumora TherapeuticsNMRA | Open-market buy | 25/10/27 | 25/10/29 | 1,915,700 sh | $2.61 | $4,999,977 | +46.4% |